BCRX

Biocryst Pharmaceuticals Inc

7.94

Oct 20 • 3:59 PM ET -0.13 (-1.61%)

7.92

Aftermarket • 7:30 PM ET -0.02 (-0.21%)

Healthcare Drug Manufacturers - Specialty & Generic USA Mid NASD

Peers: PHVS TAK IONS NTLA HRMY MIRM PTCT RYTM AGIO BMRN

| Held by: VTI XBI IWM VB VXF IWO IBB VBK VTWO SCHA

Scroll to Statements

Index	RUT
Market Cap	2.03B
Enterprise Value	2.51B
Income	-384.67M
Sales	940.61M
Book/sh	-1.78
Cash/sh	1.38
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	0.00%
Employees	435
IPO	Mar 04, 1994

P/E	-
Forward P/E	13.47
PEG	-
P/S	2.16
P/B	-
P/C	5.75
P/FCF	5.70
EV/EBITDA	6.49
EV/Sales	2.67
Quick Ratio	2.29
Current Ratio	2.32
Debt/Eq	-
LT Debt/Eq	-
Option/Short	Yes / Yes

EPS (ttm)	-1.50
EPS next Y	0.59
EPS next Q	0.09
EPS this Y	-289.41%
EPS next Y	125.72%
EPS next 5Y	-18.19%
EPS past 3/5Y	- -
Sales past 3/5Y	47.82% 117.89%
EPS Y/Y TTM	-737.08%
Sales Y/Y TTM	68.72%
EPS Q/Q	1180.09%
Sales Q/Q	33.61%
Earnings	Aug 05 BMO
EPS/Sales Surpr.	94.55% 19.08%

Insider Own	14.04%
Insider Trans	-0.20%
Inst Own	90.33%
Inst Trans	5.32%
ROA	-75.79%
ROE	-
ROIC	-114.64%
Gross Margin	97.53%
Oper. Margin	40.89%
Profit Margin	-40.90%
SMA20	-3.54%
SMA50	-11.17%
SMA200	-8.91%
Trades

Shs Outstand	255.26M
Shs Float	219.66M
Short Float	12.52%
Short Ratio	6.54
Short Interest	27.49M
52W High	11.22 -29.23%
52W Low	6.23 27.45%
Volatility	3.54% 3.75%
ATR (14)	0.32
RSI (14)	40.35
Beta	0.55
Rel Volume	2.01
Avg Volume	4.20M
Volume	8,444,800

Perf Week	-1.61%
Perf Month	-9.36%
Perf Quarter	-16.51%
Perf Half Y	-7.46%
Perf YTD	1.79%
Perf Year	14.57%
Perf 3Y	35.03%
Perf 5Y	-44.59%
Perf 10Y	76.44%
Recom	1.36
Target Price	20.55
Prev Close	8.07
Price	7.94
Change %	-1.61%

Date	Action	Analyst	Rating Change	Price Target Change
Sep-10-26	Downgrade	RBC Capital Mkts	Outperform → Sector Perform	$11
Jul-13-26	Resumed	JP Morgan	Neutral	$12
Feb-18-26	Resumed	Evercore ISI	Outperform	$17
Oct-15-25	Resumed	TD Cowen	Buy	$30
Oct-01-25	Downgrade	Evercore ISI	Outperform → In-line	$8
Apr-29-25	Initiated	Cantor Fitzgerald	Overweight	$20
Feb-25-25	Initiated	Wedbush	Outperform	$15
Nov-20-23	Resumed	JP Morgan	Overweight	$10
Sep-18-23	Upgrade	RBC Capital Mkts	Sector Perform → Outperform	$9 → $10
Aug-04-23	Upgrade	Jefferies	Hold → Buy	$11
Jul-13-23	Upgrade	BofA Securities	Neutral → Buy	$10
Feb-22-23	Upgrade	Needham	Hold → Buy	$14
Nov-02-22	Upgrade	Evercore ISI	In-line → Outperform	$14 → $16
Aug-05-22	Downgrade	Oppenheimer	Outperform → Perform
Aug-05-22	Downgrade	Evercore ISI	Outperform → In-line	$14
Apr-18-22	Downgrade	Barclays	Overweight → Equal Weight	$22 → $13
Apr-11-22	Downgrade	BofA Securities	Buy → Neutral	$21 → $14
Dec-10-21	Initiated	Oppenheimer	Outperform	$16
Aug-06-21	Downgrade	Jefferies	Buy → Hold
Aug-03-21	Initiated	Cantor Fitzgerald	Overweight	$21

Show Previous Ratings

Oct-05-26 07:00AM	BioCryst Announces Formation of Scientific Advisory Board to Drive Rare Disease Pipeline Innovation and Growth (GlobeNewswire)
Sep-21-26 02:44PM	Biopharma Stock With Layers of Technical Support in Place (Schaeffer's Research)
Sep-10-26 11:52AM	BCRX Stock Heads For Fifth Straight Day In The Red RBC Capital Says BioCryst Faces A Challenging Near-Term Outlook (Stocktwits) -5.85%
Sep-08-26 07:24PM	BCRX Stock Posts Worst Day In Over 6 Months After PHVS Trial Win In Rare Swelling Disease (Stocktwits) -8.99%
Sep-01-26 07:00AM	BioCryst to Present at Upcoming Investor Conference (GlobeNewswire)
07:40PM	Loading…
Aug-28-26 07:40PM	BioCrysts Orladeyo Built The Cash Pile, CEO Gayer Wants To Buy The Next Asset (Stocktwits)
Aug-25-26 07:01AM	BioCryst Announces Approval of ORLADEYO for Pediatric HAE Patients in Japan (GlobeNewswire)
Aug-05-26 05:05PM	BioCryst Pharmaceuticals Inc (BCRX) (Q2 2026) Earnings Call Highlights: Record Revenue and ... (GuruFocus.com)
12:50PM	BioCryst Pharmaceuticals, Inc. Q2 2026 Earnings Call Summary (Moby)
10:39AM	BioCryst Bets On Rare Genetic Disorder Therapy Expansion Amid Q2 Earnings Beat Retail Piles On Buyout Speculation (Stocktwits)
07:29AM	BioCryst: Q2 Earnings Snapshot (Associated Press)
07:00AM	BioCryst Reports Second Quarter 2026 Financial Results (GlobeNewswire)
Jul-22-26 07:00AM	BioCryst to Report Second Quarter 2026 Financial Results on August 5 (GlobeNewswire)
Jul-15-26 07:00AM	BioCryst Appoints David W. Jenkins as Chief Scientific Officer (GlobeNewswire)
Jul-08-26 11:39PM	Why Did PENG, ANET, BCRX Shares Surge To 52-Week Highs? (Stocktwits)
01:11AM	Loading…
01:11AM	VKTX Vs BCRX: Which Biotech Takeover Favorite Offers More Upside After Vertexs $10B CRNX Deal? (Stocktwits)
Jul-07-26 11:34PM	Why Did CRNX, D, BCRX Stocks Surge To 52-Week Highs Today? (Stocktwits) +8.06%
Jul-02-26 07:00AM	BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jun-29-26 07:00AM	BioCryst Sharpens Scientific Focus on External Innovation with Wind Down of Internal Discovery Programs and Closure of Birmingham Research Facility (GlobeNewswire)
Jun-25-26 12:50PM	BCRX Stock Set For Best Week In Over 3 Months Retail Shifts Focus To This Crucial Breakout Level (Stocktwits)
Jun-12-26 07:00AM	BioCryst Presents New Clinical Data and Real-World Evidence Demonstrating Impact of HAE Portfolio at the 2026 European Academy of Allergy and Clinical Immunology Annual Meeting (GlobeNewswire)
Jun-09-26 04:05PM	BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
May-27-26 07:00AM	BioCryst to Present New HAE Data from ORLADEYO (berotralstat) and Navenibart at the 2026 European Academy of Allergy and Clinical Immunology Annual Meeting (GlobeNewswire) +7.67%
May-13-26 07:00AM	BioCryst to Present New Real-World Evidence Underscoring the Ongoing Burden of Pediatric Hereditary Angioedema at ISPOR 2026 (GlobeNewswire) +9.09%
May-06-26 12:48PM	BioCryst Pharmaceuticals, Inc. Q1 2026 Earnings Call Summary (Moby)
08:12AM	BioCryst: Q1 Earnings Snapshot (Associated Press)
07:00AM	BioCryst Reports First Quarter 2026 Financial Results and Provides Business Update (GlobeNewswire)
May-05-26 07:00AM	BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
May-04-26 07:00AM	BioCryst Announces European Licensing Agreement with Irish Affiliate of Neopharmed Gentili for Navenibart in Hereditary Angioedema (GlobeNewswire)
Apr-28-26 07:00AM	BioCryst to Present at Upcoming Investor Conferences (GlobeNewswire)
07:00AM	Loading…
Apr-15-26 07:00AM	BioCryst to Report First Quarter 2026 Financial Results on May 6 (GlobeNewswire)
Apr-06-26 07:00AM	BioCryst Appoints Sandeep M. Menon Chief Research and Development Officer (GlobeNewswire)
Apr-03-26 07:00AM	BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Mar-10-26 08:02AM	BioCryst Pharma (BCRX) Subject to Prise Target Raise by Wedbush (Insider Monkey)
Mar-06-26 06:46AM	BioCryst Pharmaceuticals Conference: Profitability Pivot, ORLADEYO Growth, Navenibart Phase 3 Timeline (MarketBeat)
Mar-04-26 07:00AM	BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Feb-28-26 07:28AM	BioCryst (BCRX) Soars 10.8% on Swing to Profits (Insider Monkey)
Feb-26-26 11:53PM	Where is BioCryst Pharmaceuticals (BCRX) Headed According to the Street? (Insider Monkey) +10.76%
04:10PM	BioCryst Pharmaceuticals Inc (BCRX) Q4 2025 Earnings Call Highlights: Record Profitability and ... (GuruFocus.com)
12:15PM	BioCryst Pharmaceuticals (BCRX) Q4 Earnings and Revenues Surpass Estimates (Zacks)
12:06PM	BioCryst Pharmaceuticals Q4 Earnings Call Highlights (MarketBeat)
07:39AM	BioCryst: Q4 Earnings Snapshot (Associated Press Finance)
07:00AM	BioCryst Reports Full Year 2025 Financial Results and Provides Business Update (GlobeNewswire)
Feb-23-26 04:42PM	Evercore ISI Sees Long-Term Growth Potential For BioCryst Pharmaceuticals, Inc. (BCRX) Following Astria Acquisition (Insider Monkey)
10:00AM	Harrow (HROW) Reports Next Week: Wall Street Expects Earnings Growth (Zacks)
Feb-19-26 10:00AM	BioCryst Pharmaceuticals (BCRX) Earnings Expected to Grow: Should You Buy? (Zacks)
Feb-17-26 07:00AM	BioCryst to Present at Upcoming Investor Conference (GlobeNewswire)
Feb-11-26 07:00AM	BioCryst to Present New HAE Data from ORLADEYO (berotralstat) and Navenibart at the 2026 American Academy of Allergy, Asthma & Immunology Annual Meeting (GlobeNewswire)
Feb-07-26 12:56AM	Jim Cramer on BioCryst Pharmaceuticals: "Just Stay Away From That" (Insider Monkey)
Feb-05-26 07:01AM	BioCryst to Report Fourth Quarter 2025 Financial Results on February 26 (GlobeNewswire)
07:00AM	BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jan-30-26 07:35AM	Strength Seen in Korro Bio, Inc. (KRRO): Can Its 13.9% Jump Turn into More Strength? (Zacks)
Jan-23-26 09:00AM	BioCryst Completes Acquisition of Astria Therapeutics, Expanding Leadership in Hereditary Angioedema (GlobeNewswire)
Jan-13-26 02:04AM	BioCryst Pharmaceuticals Touts ORLADEYO Momentum, Astria Deal and 2026 Outlook at JPM Conference (MarketBeat)
Jan-12-26 07:00AM	BioCryst Announces Preliminary Full Year 2025 ORLADEYO (berotralstat) Net Revenue of $601 Million (+37 percent y-o-y), Beating Prior Guidance Range (GlobeNewswire)
Jan-06-26 07:01AM	BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
07:00AM	BioCryst to Present at 44th Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-21-25 09:57AM	H.C. Wainwright Lifts PT on BioCryst Pharmaceuticals (BCRX) to $32 From $30 (Insider Monkey)
Dec-14-25 06:05AM	Wedbush Predicts Up to ~600% Jump for These 2 Strong Buy Stocks (TipRanks)
Dec-04-25 01:09PM	Pharvaris Stock Gains on HAE Drug Meeting Late-Stage Study Goals (Zacks)
07:00AM	BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Dec-03-25 07:00AM	BioCryst Receives Early Termination of HSR Waiting Period for Astria Acquisition (GlobeNewswire) +9.64%
Nov-30-25 12:26AM	BioCryst Data Highlights Severe Psychosocial Burden of HAE on Pediatric Patients, Caregivers (Insider Monkey)
Nov-06-25 08:00AM	BioCryst Presents New Data at ACAAI Highlighting Burden of HAE on Pediatric Patients and Caregivers and Sustained Reduction of Attacks in Children Treated with One Year of ORLADEYO (berotralstat) (GlobeNewswire)
Nov-05-25 07:01AM	BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +6.07%
07:00AM	BioCryst to Present at Upcoming Investor Conference (GlobeNewswire)
Nov-03-25 04:01PM	BioCryst Pharmaceuticals Inc (BCRX) Q3 2025 Earnings Call Highlights: Strong Orladeo Growth and ... (GuruFocus.com) -6.28%
07:12AM	BioCryst: Q3 Earnings Snapshot (Associated Press Finance)
07:00AM	BioCryst Reports Third Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire)
Oct-31-25 05:42PM	Astria, Viridian Therapeutics, and More Stocks See Action From Activist Investors (Barrons.com)
Oct-30-25 05:40PM	Ardelyx (ARDX) Reports Break-Even Earnings for Q3 (Zacks)
Oct-28-25 10:00AM	Madrigal (MDGL) Expected to Beat Earnings Estimates: Should You Buy? (Zacks)
Oct-27-25 10:00AM	BioCryst Pharmaceuticals (BCRX) Earnings Expected to Grow: Should You Buy? (Zacks)
Oct-23-25 07:00AM	BioCryst to Present New Pediatric HAE Data at the American College of Allergy, Asthma & Immunology 2025 Annual Scientific Meeting (GlobeNewswire)
Oct-20-25 07:00AM	BioCryst to Report Third Quarter 2025 Financial Results on November 3 (GlobeNewswire)
Oct-16-25 07:56AM	BioCryst (BCRX) Soars 6.1%: Is Further Upside Left in the Stock? (Zacks)
Oct-15-25 10:05AM	Astria Therapeutics Stock Rallies 37% on $700M Buyout Offer From BCRX (Zacks) +6.07%
09:17AM	Teladoc Health Expands Clarity Platform With Workplace Safety Tool (Zacks)
05:16AM	BioCryst to buy Astria Therapeutics for $700m in enterprise value (Pharmaceutical Technology)
Oct-14-25 08:59AM	Is the Options Market Predicting a Spike in BioCryst Pharmaceuticals Stock? (Zacks) -8.81%
07:32AM	BioCryst goes all in on rare swelling disease with Astria deal (BioPharma Dive)
07:00AM	BioCryst to Acquire Astria Therapeutics, Strengthening Presence in HAE, Transforming Growth Profile (Business Wire)
Oct-07-25 09:35AM	Down 14.3% in 4 Weeks, Here's Why BioCryst (BCRX) Looks Ripe for a Turnaround (Zacks)
Oct-04-25 04:54PM	BioCryst Sells European ORLADEYO Business for $250M Upfront to Focus on US Market (Insider Monkey)
Oct-03-25 07:00AM	BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Oct-01-25 07:00AM	BioCryst Completes Sale of European ORLADEYO (berotralstat) Business (GlobeNewswire)
Sep-11-25 08:31AM	BofA lists 13 SMID cap stocks that could rebound (Investing.com)
Sep-03-25 07:00AM	BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Sep-02-25 04:04AM	BioCryst Pharmaceuticals, Inc. (BCRX) Q2 Revenue Soars 49%, Hits Record $163.4 Million on ORLADEYO Surge (Insider Monkey)
Aug-21-25 07:00AM	BioCryst to Present at Upcoming Investor Conference (GlobeNewswire)
Aug-12-25 05:41PM	Are Options Traders Betting on a Big Move in BCRX Stock? (Zacks)
Aug-11-25 07:00AM	BioCryst Announces Departure of Dr. Helen Thackray (GlobeNewswire)
Aug-06-25 07:00AM	BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Aug-05-25 03:00AM	BioCryst Pharmaceuticals Inc (BCRX) Q2 2025 Earnings Call Highlights: Record ORLADEYO Revenue ... (GuruFocus.com)
Aug-04-25 08:15AM	BioCryst Pharmaceuticals (BCRX) Surpasses Q2 Earnings and Revenue Estimates (Zacks) +9.81%
07:12AM	BioCryst: Q2 Earnings Snapshot (Associated Press Finance)
07:00AM	BioCryst Reports Second Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire)
Jul-31-25 01:12PM	BioCryst Pharmaceuticals Before Q2 Earnings: How to Play the Stock (Zacks)
07:00AM	BioCryst Announces Charlie Gayer to Succeed Jon Stonehouse as Chief Executive Officer Upon his Retirement in December (GlobeNewswire)
Jul-29-25 10:00AM	Analysts Estimate Esperion Therapeutics (ESPR) to Report a Decline in Earnings: What to Look Out for (Zacks)

Show Previous News

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
McKee Amy E	Director	May 18 '26	Sale	8.97	11,180	100,285	31,252	May 19 04:07 PM
Amy McKee	Director	May 18 '26	Proposed Sale	8.94	11,180	99,906		May 18 04:48 PM
Barnes Alane P	Chief Legal Officer	May 13 '26	Option Exercise	5.04	62,500	315,000	463,203	May 15 04:08 PM
Barnes Alane P	Chief Legal Officer	May 13 '26	Sale	9.54	62,500	596,250	400,703	May 15 04:08 PM
Barnes Alane P	Officer	May 13 '26	Proposed Sale	9.54	62,500	596,250		May 13 01:06 PM
HEGGIE THERESA	Director	Mar 20 '26	Option Exercise	6.30	49,933	314,578	115,285	Mar 24 04:02 PM
HEGGIE THERESA	Director	Mar 20 '26	Sale	10.11	49,933	504,823	65,352	Mar 24 04:02 PM
HEGGIE THERESA	Director	Mar 20 '26	Proposed Sale	10.11	49,933	504,620		Mar 20 11:36 AM
Barnes Alane P	Chief Legal Officer	Mar 16 '26	Option Exercise	5.51	150,000	826,500	550,703	Mar 18 04:11 PM
Barnes Alane P	Chief Legal Officer	Mar 16 '26	Sale	9.15	150,000	1,372,500	400,703	Mar 18 04:11 PM
Barnes Alane P	Officer	Mar 16 '26	Proposed Sale	9.15	150,000	1,372,007		Mar 16 04:17 PM
Stonehouse Jon P	Director	Mar 02 '26	Option Exercise	3.22	305,995	985,304	1,629,845	Mar 03 04:34 PM
Stonehouse Jon P	Director	Mar 02 '26	Proposed Sale	8.65	305,995	2,646,857		Mar 02 03:16 PM
Barnes Alane P	Chief Legal Officer	Dec 22 '25	Sale	7.65	21,773	166,563	398,751	Dec 23 04:11 PM
Gayer Charles K	President and CCO	Dec 22 '25	Option Exercise	5.01	74,233	371,896	952,583	Dec 23 04:08 PM
Barnes Alane P	Officer	Dec 22 '25	Proposed Sale	7.65	21,773	166,563		Dec 22 01:27 PM
Barnes Alane P	Chief Legal Officer	Dec 15 '25	Sale	7.65	21,210	162,256	315,726	Dec 16 04:13 PM
Barnes Alane P	Officer	Dec 15 '25	Proposed Sale	7.65	21,210	162,256		Dec 15 10:48 AM
Barnes Alane P	Chief Legal Officer	Dec 01 '25	Option Exercise	3.22	91,004	293,033	507,156	Dec 03 06:40 PM
Barnes Alane P	Chief Legal Officer	Dec 01 '25	Sale	7.10	91,004	646,511	416,152	Dec 03 06:40 PM
Barnes Alane P	Chief Legal Officer	Dec 02 '25	Sale	7.21	50,906	367,216	365,246	Dec 03 06:40 PM
Barnes Alane P	Chief Legal Officer	Dec 03 '25	Sale	7.65	19,770	151,240	345,476	Dec 03 06:40 PM
Barnes Alane P	Officer	Dec 03 '25	Proposed Sale	7.65	19,770	151,240		Dec 03 02:01 PM
Barnes Alane P	Officer	Dec 02 '25	Proposed Sale	7.21	50,906	367,216		Dec 02 02:09 PM
Barnes Alane P	Officer	Dec 01 '25	Proposed Sale	7.08	91,004	644,308		Dec 01 12:51 PM
Helen M Thackray	Officer	Nov 25 '25	Proposed Sale	6.80	48,229	327,957		Nov 25 04:31 PM
Helen Thackray	Officer	Nov 21 '25	Proposed Sale	7.11	43,275	307,685		Nov 21 04:29 PM
SANDERS MACHELLE	Director	Nov 13 '25	Sale	7.14	9,600	68,544	30,642	Nov 17 04:07 PM
SANDERS MACHELLE	Officer	Nov 13 '25	Proposed Sale	7.14	9,600	68,544		Nov 13 10:21 AM

BioCryst Pharmaceuticals, Inc. is a biotechnology company. It engages in the provision of structure-guided drug design with the goal of developing oral small-molecule and protein therapeutics to target difficult-to-treat rare diseases. The company was founded by William M. Spencer III, Charles E. Bugg, and John A. Montgomery in 1986 and is headquartered in Durham, NC.

CEOMr. Charles K. Gayer

CFO & Head of Corporate DevelopmentMr. Babar Ghias

Senior VPMs. Alane P. Barnes

Chief Technical Operations OfficerMr. John Ruesch

Ph.D.Dr. David W. Jenkins M.A.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

BCRX

Biocryst Pharmaceuticals Inc

Upgrade your Finviz experience